325 related articles for article (PubMed ID: 34385259)
1. The
Simoneau A; Xiong R; Zou L
Genes Dev; 2021 Sep; 35(17-18):1271-1289. PubMed ID: 34385259
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
3. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
[TBL] [Abstract][Full Text] [Related]
4. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
6. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
[TBL] [Abstract][Full Text] [Related]
7. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
8. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
10. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
15. Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Panzarino NJ; Krais JJ; Cong K; Peng M; Mosqueda M; Nayak SU; Bond SM; Calvo JA; Doshi MB; Bere M; Ou J; Deng B; Zhu LJ; Johnson N; Cantor SB
Cancer Res; 2021 Mar; 81(5):1388-1397. PubMed ID: 33184108
[TBL] [Abstract][Full Text] [Related]
16. ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms.
Leung W; Simoneau A; Saxena S; Jackson J; Patel PS; Limbu M; Vindigni A; Zou L
Cell Rep; 2023 Jul; 42(7):112792. PubMed ID: 37454295
[TBL] [Abstract][Full Text] [Related]
17. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
18. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
19. REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
Taglialatela A; Leuzzi G; Sannino V; Cuella-Martin R; Huang JW; Wu-Baer F; Baer R; Costanzo V; Ciccia A
Mol Cell; 2021 Oct; 81(19):4008-4025.e7. PubMed ID: 34508659
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
